Citrate Pharmacokinetics in Critically Ill Liver Failure Patients Receiving CRRT
NCT ID: NCT04959110
Last Updated: 2022-11-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
20 participants
INTERVENTIONAL
2019-07-01
2021-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Citrate Pharmacokinetics and Regional Citrate Anticoagulation in CRRT
NCT00948558
Metabolic Aspects of Citrate Anticoagulation in Renal Replacement Therapy
NCT01361581
Nafamostat Mesilate for Anticoagulation During CRRT in Critically Ill Patients
NCT05382078
The Effect of Citrate Dialysate on Clot Formation and Anemia in Hemodialysis Patients
NCT03470727
Citrate Anticoagulation for Postdilution Hemofiltration
NCT03969966
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Acute Liver Failure
Acute liver failure critically ill patients receiving CRRT
Pharmacokinetic study
* Start CVVH session with isotonic citrate solution (13.3 mmol/L) as predilution, targeting citrate dose at 3 mmol/L
* Blood samples collection at pre-filter for citrate concentration, blood gas, electrolyte and ionized calcium and magnesium
* In addition, 10 minutes after the end of citrate infusion, blood samples were taken simultaneously from both pre-filter and post-filter to calculate citrate clearance by filter
Acute on top Chronic Liver Failure
Acute on top chronic liver failure critically ill patients receiving CRRT
Pharmacokinetic study
* Start CVVH session with isotonic citrate solution (13.3 mmol/L) as predilution, targeting citrate dose at 3 mmol/L
* Blood samples collection at pre-filter for citrate concentration, blood gas, electrolyte and ionized calcium and magnesium
* In addition, 10 minutes after the end of citrate infusion, blood samples were taken simultaneously from both pre-filter and post-filter to calculate citrate clearance by filter
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Pharmacokinetic study
* Start CVVH session with isotonic citrate solution (13.3 mmol/L) as predilution, targeting citrate dose at 3 mmol/L
* Blood samples collection at pre-filter for citrate concentration, blood gas, electrolyte and ionized calcium and magnesium
* In addition, 10 minutes after the end of citrate infusion, blood samples were taken simultaneously from both pre-filter and post-filter to calculate citrate clearance by filter
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* aged ≥ 18 y old
* Currently receiving CRRT.
Exclusion Criteria
* blood transfusion within 24 h prior to the study
* use of citrate-containing medications
* severe hypocalcemia (serum ionized calcium \< 0.8 mmol/L)
* use of heparin as anticoagulation
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Chulalongkorn University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Nattachai Srisawat ,M.D.
Director of Excellence Center for Critical Care Nephrology
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Chulalongkorn university
Bangkok, , Thailand
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IRB.694/63
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.